Application
ICC/IF analysis of HeLa cells using Caspase 8 antibody [EPR162] at a dilution of 1:100.Application
WB analysis of lysates from (1) etoposide-treated Jurkat, (2) untreated Jurkat, (3) staurosporine-treated HeLa and (4) untreated HeLa cells (10 μg per lane) using Caspase 8 antibody [EPR162] at a dilution of 1:1,000.Application
IHC-P analysis of human hepatocellular carcinoma using Caspase 8 antibody [EPR162] at a dilution of 1:100.| Product Name | Caspase 8 antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit monoclonal antibody [EPR162] to Caspase 8This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been des |
| Immunogen | Synthetic peptide corresponding to human Caspase-8 aa 200-300 (internal sequence). |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Clone Number | EPR162 |
| Host Species | Rabbit |
| Tested Applications | ICC/IFIHC-PWB |
| Recommended Starting Dilutions:
For WB: Use at a dilution of 1:1000 - 1:10000.
For IHC-P: Use at a dilution of 1:100 - 1:250.
For ICC/IF: Use at a dilution of 1:100 - 1:250.
Optimal dilutions should be determined experimentally by the researcher.: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | CASP8 Casp-8 MCH5 MACH caspase 8 apoptosis-related cysteine peptidase ALPS2B FLICE CAP4 |
|---|---|
| Target | Caspase 8 |
Application
ICC/IF analysis of HeLa cells using Caspase 8 antibody [EPR162] at a dilution of 1:100.
Application
WB analysis of lysates from (1) etoposide-treated Jurkat, (2) untreated Jurkat, (3) staurosporine-treated HeLa and (4) untreated HeLa cells (10 μg per lane) using Caspase 8 antibody [EPR162] at a dilution of 1:1,000.
Application
IHC-P analysis of human hepatocellular carcinoma using Caspase 8 antibody [EPR162] at a dilution of 1:100.| Application Notes | Recommended Starting Dilutions:
For WB: Use at a dilution of 1:1000 - 1:10000.
For IHC-P: Use at a dilution of 1:100 - 1:250.
For ICC/IF: Use at a dilution of 1:100 - 1:250.
Optimal dilutions should be determined experimentally by the researcher.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at -20°C. Stable for 12 months at -20°C |
| Storage Buffer | PBS containing 50% Glycerol, 0.05% BSA and 0.01% Sodium azide. |
